Liquidia Corporation Common Stock vs ProShares Ultra QQQ ETF — how do they compare? Liquidia Corporation Common Stock trades at $33.47 (market cap $3.04B), while ProShares Ultra QQQ ETF trades at $90.38 (market cap $15.24B). The key difference: ProShares Ultra QQQ ETF is far larger — about 5× Liquidia Corporation Common Stock's market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| LQDA | QLD | |
|---|---|---|
Market Cap | $3.04B | $15.24B |
Volume | 21,111,778 | 4,894,545 |
Sector | Health | Leveraged / Inverse |
52-Week High | $91.03 | $100.77 |
52-Week Low | $22.02 | $57.16 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $2.94B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QLD (ProShares Ultra QQQ ETF) trades at $96.42, down 0.68% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF provides 2x leveraged exposure to the Nasdaq-100 index, offering amplified returns during market rallies while being less volatile than 3x leveraged alternatives. Recent institutional buying activity and media coverage highlight continued investor interest in leveraged tech exposure.
The outlook for QLD remains tied to Nasdaq-100 performance, with technical support at $95-$97 providing a cushion. However, leveraged ETF risks including decay during volatile periods and sensitivity to Federal Reserve policy require careful monitoring. The 2x structure offers a balanced approach for investors seeking amplified tech exposure without extreme volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →